Evgen reported full-year results to 31 March that were c.£0.3m better than expected, resulting in year-end cash of £2.0m. Together with a £5m placing in May, the company is funded through to mid-2021 at its current run rate. Whilst we await the Phase IIb trial read-out for SFX-01 in sub-arachnoid haemorrhage (SAH) in late Q3/early Q4, the company continues to plan for a placebo-controlled Phase IIb trial in metastatic breast cancer (mBC), which, funding-permitting, could start in H2 2019. We rei ....
13 Jun 2019
Evgen Pharma - Full-year results – await SAH Phase IIb data
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Evgen Pharma - Full-year results – await SAH Phase IIb data
Evgen Pharma Plc (EVG:LON) | 0.9 0 0.0% | Mkt Cap: 2.41m
- Published:
13 Jun 2019 -
Author:
Mark Brewer -
Pages:
12
Evgen reported full-year results to 31 March that were c.£0.3m better than expected, resulting in year-end cash of £2.0m. Together with a £5m placing in May, the company is funded through to mid-2021 at its current run rate. Whilst we await the Phase IIb trial read-out for SFX-01 in sub-arachnoid haemorrhage (SAH) in late Q3/early Q4, the company continues to plan for a placebo-controlled Phase IIb trial in metastatic breast cancer (mBC), which, funding-permitting, could start in H2 2019. We rei ....